Synta Pharmaceuticals reports Q1 EPS 28c, consensus 29c The company said, "There were no revenues recognized in 1Q14 and 1Q13. Research and development expenses were $17.6M for Q1." Reports Q1 General and administrative expenses $5.3M. Q1 revenue consensus $450K.
News For SNTA From The Last 14 Days
Check below for free stories on SNTA the last two weeks.